Polyposis in Lynch syndrome: A retrospective study

Table 1 Characteristics of the study population

	Total cohort (n = 257)
Age at first colonoscopy, year, mean ± SD (range)	45.5 ± 14.3 (19-87)
Sex
Male	89 (34.6)
Female	168 (65.4)
Race
White	245 (95.3)
Black	7 (2.7)
Hispanic	1 (0.4)
Asian	3 (1.2)
Native American	1 (0.4)
Current smoker	40 (15.6)
BMI in kg/m2, mean ± SD (range)	28.8 ± 6.4 (17.4-53.9)
First-degree relative with CRC, yes	134 (52.1)
Second-degree relative with CRC, yes	148 (58.0)
Medication use
Aspirin use (yes)	50 (19.5)
Statin use (yes)	32 (12.5)
NSAID use (yes)	43 (16.7)
Affected gene
EPCAM	2 (0.8)
MLH1	51 (19.8)
MSH2	90 (35.0)
MSH6	64 (24.9)
PMS2	50 (19.5)
Diagnosis of CRC, yes	88 (34.2)
Age at CRC diagnosis in years, mean ± SD (range)	49.6 ± 13.5 (24-87)
Colectomy
Partial	50 (19.5)
Sub-total/total	28 (10.9)
None	179 (69.6)
Age at first polyp in years, mean ± SD (range)	49.2 ± 13.4 (22-87)
Number of colonoscopies, mean ± SD (range)	4.7 ± 3.5 (1-23)
Number of adenomas, mean ± SD (range)	2.4 ± 4.6 (0-44)
Diagnosed with ≥ 10 adenomas, yes	11 (4.3)
Time followed in years, mean ± SD (range)	6.8 ± 6.7 (0-36)

BMI: Body mass index; CRC: Colorectal cancer; NSAID: Non-steroidal anti-inflammatory drug.

Table 2 Characteristics of patients with ≥ 10 adenomas

Patient	Age at first colonoscopy (year)	Age of LS diagnosis	Sex	Race	PV	Total lifetime adenomas	Diagnosis of CRC, age (year)	Surgery, age (year)	First-degree relative with CRC	Second-degree relative with CRC
1	26	31	Male	White	MSH2	44	Yes, 50	Total colectomy, 50	Yes	Yes
2	45	54	Female	White	MSH6	39	Yes, 41	Sigmoidectomy, 41	No	No
3	64	66	Female	White	MSH6	25	No	No	No	Yes
4	59	61	Female	White	MSH6	19	No	No	No	No
5	40	40	Male	White	MSH6	15	No	No	No	No
6	47	57	Male	White	MSH2	13	Yes, 55	No	Yes	Yes
7	44	50	Male	White	MSH6	10	No	No	Yes	Yes
8	51	53	Female	White	MSH2	10	No	No	Yes	Yes
9	50	62	Female	White	MSH2	10	No	No	Yes	Yes
10	34	34	Male	White	MSH2	10	Yes, 34	Proctectomy, 34	Yes	No
11	74	88	Male	Black	PMS2	10	Yes, 80	Transverse colectomy, 80	Yes	No

CRC: Colorectal cancer; PV: Pathogenic variant.

Table 3 Participants with ≥ 6 colonoscopies, stratified by number of adenomas (< 10, ≥ 10)

	Participants with ≥ 6 colonoscopies (n = 92)
	< 10 lifetime adenomas (n = 81)	≥ 10 lifetime adenomas (n = 11)	P value
Age at first colonoscopy, year, mean ± SD (range)	47.1 ± 12.5 (20-72)	48.9 ± 13.6 (26-75)	0.51
Sex			0.33
Male	25 (30.9)	6 (54.5)
Female	56 (69.1)	5 (45.5)
Race			0.70
White	73 (90.1)	10 (90.9)
Black	5 (6.2)	1 (9.1)
Hispanic	1 (1.2)	0 (0.0)
Asian	1 (1.2)	0 (0.0)
Native American	1 (1.2)	0 (0.0)
Current smoker	9 (11.3)	1 (9.1)	1.00
BMI in kg/m2, mean ± SD (range)	27.9 ± 5.9 (18-50)	29.7 ± 6.2 (18.7-38.4)	0.38
First-degree relative with CRC, yes	45 (55.6)	7 (63.6)	0.75
Second-degree relative with CRC, yes	47 (58.8)	6 (54.6)	1.00
Medication use
Aspirin use (yes)	18 (22.2)	3 (27.3)	0.71
Statin use (yes)	7 (8.6)	2 (18.2)	0.29
NSAID use (yes)	11 (13.6)	2 (18.2)	0.65
Affected gene			0.28
EPCAM	1 (1.2)	0 (0.0)
MLH1	18 (22.2)	0 (0.0)
MSH2	29 (35.8)	5 (45.5)
MSH6	20 (24.7)	5 (45.5)
PMS2	13 (16.1)	1 (9.1)
Diagnosis of CRC, yes	43 (53.1)	5 (45.5)	0.75
Age at CRC diagnosis in years, mean ± SD (range)	48.6 ± 12.0 (24-70)	52.6 ± 17.5 (35-80)	0.80
Colectomy			1.00
Partial	25 (30.9)	2 (18.2)
Sub-total/total	12 (14.8)	1 (9.1)
None	44 (54.3)	8 (72.7)
Age at first polyp in years, mean ± SD (range)	49.7 ± 11.9 (22-70)	50.7 ± 14.9 (27-80)	0.87
Number of colonoscopies, mean ± SD (range)	8.1 ± 2.3 (6-16)	11.2 ± 4.7 (6-23)	0.01
Number of adenomas, mean ± SD (range)	2.7 ± 2.2 (0-9)	18.7 ± 12.3 (10-44)	< 0.0001
Time followed in years, mean ± SD (range)	12.2 ± 6.7 (4-36)	13.1 ± 5.4 (5-26)	0.23

CRC: Colorectal cancer; NSAID: Non-steroidal anti-inflammatory drug.